Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
Grantová podpora
CIHR - Canada
PubMed
32124552
DOI
10.1002/pbc.28228
Knihovny.cz E-zdroje
- Klíčová slova
- NF2, bevacizumab, brain tumors, vestibular schwannomas,
- MeSH
- bevacizumab aplikace a dávkování MeSH
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- neurofibromin 2 metabolismus MeSH
- vestibulární schwannom farmakoterapie metabolismus patologie patofyziologie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- bevacizumab MeSH
- neurofibromin 2 MeSH
- NF2 protein, human MeSH Prohlížeč
Seventeen children at six institutions with neurofibromatosis type 2 (NF2)-related vestibular schwannomas received bevacizumab. Eight of the 13 patients with initial hearing loss (61%) showed objective hearing improvement within six months of treatment. No patients showed hearing deterioration during therapy; however, only two patients showed objective radiological response. Seven of eight patients had tumor progression or worsening hearing loss upon cessation of treatment. Bevacizumab was well tolerated with no patients discontinuing therapy. Bevacizumab appears to postpone hearing loss in childhood NF2-associated vestibular schwannomas, but responses are not durable, suggesting that either longer maintenance therapy or new strategies are required.
Children's Cancer Centre Royal Children's Hospital Melbourne Australia
Department of Medical Biophysics and Paediatrics University of Toronto Toronto Ontario Canada
Division of Cancer Murdoch Children's Research Institute Melbourne Australia
Division of Haematology Oncology Hospital for Sick Children Toronto Ontario Canada
Division of Haematology Oncology Schneider Medical Center of Israel Petah Tikva Israel
Sackler Medical School Tel Aviv University Tel Aviv Israel
Service of Hematology Oncology Hospital JP Garrahan Buenos Aires Argentina
Zobrazit více v PubMed
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45(5):575-578.
National Institutes of Health Consensus Development Conference statement on acoustic neuroma, December 11-13, 1991. The consensus development panel. Arch Neurol. 1994;51(2):201-207.
Evans DG. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med. 2009;11(9):599-610.
Halliday J, Rutherford SA, McCabe MG, Evans DG. An update on the diagnosis and treatment of vestibular schwannoma. Expert Rev Neurother. 2018;18(1):29-39.
Sriskandan N, Connor SEJ. The role of radiology in the diagnosis and management of vestibular schwannoma. Clin Radiol. 2011;66(4):357-365.
Plotkin SR, Stemmer-Rachamimov AO, Barker FG, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367.
Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046-1052.
Morris KA, Golding JF, Axon PR, et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract. 2016;3(4):281-289.
Huang V, Bergner AL, Halpin C, et al. Improvement in Patient-reported hearing after treatment with bevacizumab in people with neurofibromatosis type 2. Otol Neurotol. 2018;39(5):632-638.
Plotkin SR, Merker VL, Muzikansky A, Barker FGI, Slattery WI. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol. 2014;35(1):e50-e56.
Plotkin SR, Duda DG, Muzikansky A, et al. Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol. 2019;37(35):3446-3454.
Blakeley JO, Ye X, Duda DG, et al. Efficacy and Biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol. 2016;34(14):1669-1675.
Sverak P, Adams ME, Haines SJ, et al. Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on patient-reported outcomes and toxicities. Otolaryngol Head Neck Surg (1979). 2018;160(3):526-532.
Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014;73(6):1197-1204.
